[1] Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis [J].Lancet Glob Health,2016, 4(9): e609-e616.
[2] Rumfield C S, Roller N,Pellom S T, et al. Therapeutic Vaccines for HPV-Associated Malignancies[J]. Immunotargets Ther.2020,10(9): 167-200.
[3] Sanjosé S, Brotons M, Pavón M.The natural history of human papillomavirus infection[J].Best Pract Res Clin Obstet Gynaecol, 2018, 47: 2-13.
[4] Choi Y J, Hur S Y, Kim T J, et al. A phase Ⅱ, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3[J]. Clin Cancer Res, 2020, 26(7): 1616-1623.
[5] Youn J W, Hur S Y, Woo J W, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(12): 1653-1660.
[6] Trimble C L, Morrow M P, Kraynyak K A, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial[J].Lancet, 2015, 386(10008): 2078-2088.
[7] Bhuyan P K, Dallas M, Kraynyak K, et al. Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL[J]. Hum Vaccin Immunother, 2020, 11: 1-6.
[8] Aggarwal C. Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids)+INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results[J].J Immunother Cancer, 2015, 3(Suppl 2): 426.
[9] Hillemanns P, Petry K U, Woelber L, et al.Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase Ⅰ/Ⅱa trial[J]. AACR Annual Meeting, 2019, Atlanta, GA.
[10] Alvarez R D, Huh W K, Bae S, et al.A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3)[J].Gynecol Oncol, 2016, 140(2): 245-252.
[11] Chandra J, Woo W P, Finlayson N, et al. A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)[J]. Cancer Immunol Immunother, 2021, 70(3): 743-753.
[12] Hasan Y, Furtado L, Tergas A, et al. A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 107(3): 487-498.
[13] Poelgeest M I, Welters M J, Vermeij R, et al. Vaccination against oncoproteins of HPV16 for noninvasive vulvar/Vaginal lesions: lesion clearance is related to the strength of the T-Cell response[J]. Clin Cancer Res, 2016, 22(10): 2342-2350.
[14] Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial[J].JAMA Oncol, 2019, 5(1): 67-73.
[15] Melief C J, Welters M J, Vergote I, et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival [J]. Sci Transl Med, 2020, 12(535): eaaz8235.
[16] Coleman H N, Greenfield W W, Stratton S L, et al.Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination[J].Cancer Immunol Immunother, 2016, 65(5): 563-573.
[17] Reuschenbach M, Pauligk C, Karbach J, et al.A Phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers[J].Cancer, 2016, 122(9): 1425-1433.
[18] Davidson E J, Faulkner R L, Sehr P, et al.Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)[J].Vaccine, 2004, 22(21-22): 2722-2729.
[19] Daayana S, Elkord E, Winters U, et al. Phase Ⅱ trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia[J].Br J Cancer,2010, 102(7): 1129-1136.
[20] Derkay C S, Smith R J, McClay J, et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial[J]. Ann Otol Rhinol Laryngol, 2005, 114(9): 730-737.
[21] Palefsky J M, Berry J M, Jay N, et al.A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals[J].AIDS, 2006, 20(8): 1151-1155.
[22] Roman L D, Wilczynski S, Muderspach L I, et al.A phase Ⅱ study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia[J].Gynecol Oncol, 2007, 106(3): 558-566.
[23] Van Doorslaer K, Reimers L L, Studentsov Y Y, et al. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia [J]. Gynecol Oncol, 2010, 116(2): 208-212.
[24] Huh W K, Dizon D S, Powell M A, et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: results from stage Ⅰ of the phase Ⅱ GOG/NRG0265 study[J]. J Clin Oncol, 2016, 34(15-Suppl): 5516.
[25] Basu P, Mehta A, Jain M, et al. A randomized phaseⅡstudy of ADXS11-001 listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer[J]. Int J Gynecol Cancer,2018, 28(4): 764-772.
[26] Huh W K, Brady W E, Fracasso P M, et al. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study[J]. Gynecol Oncol, 2020, 158(3): 562-569.
[27] Safran H, Leonard K L, Perez K, et al. Tolerability of ADXS11-001 Lm-LLO Listeria-based immunotherapy with mitomycin, fluorouracil, and radiation for anal cancer[J].Int J Radiat Oncol Biol Phys, 2018, 100(5): 1175-1178.
[28] Eng C, Fakih M, Amin M, et al. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer[J]. Oncotarget, 2020, 11(15): 1334-1343.
[29] Taghinezhad S S, Mohseni A H, Keyvani H, et al. Phase 1 safety and immunogenicity trial of recombinant lactococcus lactis expressing human papillomavirus type 16 E6 oncoprotein vaccine[J].Mol Ther Methods Clin Dev, 2019, 29(15): 40-51.
[30] Park Y C, Ouh Y T, Sung M H, et al. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3[J]. J Gynecol Oncol, 2019, 30(6): e88.
[31] Kaufmann A M, Stern P L, Rankin E M, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer[J].Clin Cancer Res,2002, 8(12): 3676-3685.
[32] Baldwin P J, Burg S H, Boswell C M, et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia[J].Clin Cancer Res,2003, 9(14): 5205-5213.
[33] Harper D M, Nieminen P, Donders G, et al.The efficacy and safety of tipapkinogen sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: randomized controlled phase Ⅱ trial with 2.5 years of follow-up [J].Gynecol Oncol, 2019, 153(3): 521-529.
[34] Le Tourneau C, Delord J, Cassier P, et al. Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers[J]. Ann Oncol, 2019, 30(Supplement_5): v494-v495.
[35] Rosales R, LópezContreras M, Rosales C, et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine[J].Hum Gene Ther,2014, 25(12): 1035-1049.
[36] Cabo Beltran O R, Rosales Ledezma R. MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis[J]. Head Neck, 2019, 41(3): 657-665.
[37] Kumar S, Biswas M, Jose T. HPV vaccine: current status and future directions[J]. Med J Armed Forces India,2015, 71(2): 171-177.
[38] Santin A D, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial[J].J Virol,2008, 82(4): 1968-1979.
[39] Rahma O E, Herrin V E, Ibrahim R A, et al. Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer [J].J Transl Med,2014, 12(1): 353.
[40] Stevanovic S, Draper L M, Langhan M M, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells [J].J Clin Oncol,2015, 33(14): 1543-1550.
[41] Stevanovic S, Helman S R, Wunderlich J R, et al. A phase Ⅱ study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers[J]. Clin Cancer Res, 2019, 25(5): 1486-1493.
[42] Doran S L, Stevanovic S, Adhikary S, et al. T-Cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase Ⅰ/Ⅱ study[J].J Clin Oncol, 2019, 37(30): 2759-2768.